Exonhit, Pfizer Collaborate on Alzheimer's Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.

Exonhit's Genome-Wide SpliceArray platform will be used to identify progression and other biomarkers "that could segregate healthy elderly controls, patients with mild cognitive impairment … and patients with AD," the Paris-based company said.

Pfizer will provide samples from each of the three patient groups for the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.